Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Veterinary Autoimmune Disease Therapeutics Market

Veterinary Autoimmune Disease Therapeutics Market Share

Report ID: GMI6228
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Veterinary Auto-immune Therapeutics Market Share

The prominent players in the veterinary auto-immune therapeutics market are :

Aratana Therapeutics inc.
Pfizer Inc.
Vet-Stem Inc.
Ambrx Inc.
Taconic Biosciences Inc.
JBS United
Virbac
Eli Lily and Company
Jaguar Animal Health Inc.

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market for veterinary auto-immune therapeutics size was worth USD 3.1 billion in 2022 and is set to reach USD 5.2 billion in 2032 with a 5.3% CAGR from 2023 to 2032 driven by the increasing threat of transfer of zoonotic diseases among humans, rising incidence of auto-immune diseases in livestock animals and increasing awareness and diagnosis of autoimmune diseases.

The corticosteroids segment generated USD 1.1 billion in revenue in 2022 and is expected to grow significantly attributed to the increasing demand for corticosteroids as it helps in reducing the severity of symptoms and provide relief to affected animals.

The North America veterinary auto-immune therapeutics market is expected to reach USD 2.2 billion in 2032 with a 5.5% CAGR from 2023-2032 attributed to the large population of companion animals, including dogs, cats, and horses across the region.

Aratana Therapeutics Inc., Pfizer Inc., Vet-Stem Inc., Ambrx Inc., Taconic Biosciences Inc., JBS United, Virbac, Eli Lily and Company, and Jaguar Animal Health Inc. are some of the top enterprises engaged in the industry